Has Bryon Gentile Ii, MD received payments from drug or device companies?

Yes. Drug and device makers reported $234,933 in general payments to Bryon Gentile Ii, MD across 252 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bryon Gentile Ii, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bryon Gentile Ii, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bryon Gentile Ii, MD

Cardiovascular Disease · Worcester, MANPI 1821258179

Payments from drug & device makers

$234,933in general payments, 2019–2025

Across 252 payments — averaging $932.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$231K
Abbott$3K

What the payments were for

Consulting fees$26,50611%
Speaking & faculty fees$173,35674%
Travel & lodging$28,77612%
Food & beverage$6,2953%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	222	$231,475
Abbott	30	$3,459

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$234,933 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$128,637

Medicare patients

3,167

Services billed

4,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	127	$147,517
EntrestoSacubitril/Valsartan	92	$95,780
Repatha SureclickEvolocumab	32	$31,829
FarxigaDapagliflozin Propanediol	32	$26,878
JardianceEmpagliflozin	20	$18,166
Rosuvastatin Calcium	157	$4,963
Metoprolol Succinate	275	$4,885
Ezetimibe	80	$4,702
Atorvastatin Calcium	197	$2,912
Valsartan	48	$2,103
Losartan Potassium	78	$1,368
Diltiazem 24hr Er (Cd)Diltiazem Hcl	33	$1,150
Carvedilol	106	$1,082
Amlodipine Besylate	117	$817
Torsemide	26	$694

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Worcester

Marc SabatineBoston$31.2M
Stephen WiviottBoston$29.2M
David MorrowBoston$19M
Scott SolomonBoston$16.2M
Paul RidkerBoston$16.2M
Mohit JainBoston$13M
Calum MacraeBoston$11.4M
Benjamin SciricaBoston$11.3M
Robert GiuglianoBoston$10.5M
Erin BohulaBoston$10M

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →